Newly Diagnosed Multiple Myeloma Treatments

Treatments in Development

The following is a list of treatments in development for newly diagnosed multiple myeloma that are currently recruiting myeloma patients in the United States. You can use the buttons below to filter by diagnosis and sort the listings by name, distance as well as active number of trials.


Other ways to search
Find a trial that's right for you by personalizing your search.
Browse our myeloma treatment center directory to find a myeloma specialist near you.

Sort By Distance

Need Help?

Call SparkCures and one of our clinical trial specialists will help answer your questions.

(888) 828-2206

Allogeneic Transplant
Allogeneic Transplant is a type of stem cell transplant that utilizes a donor (not from own) pre-collected stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
Autologous Transplant
Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
Azacitidine (Vidaza)
Azacitidine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat myelodysplastic syndromes (MDS). It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Bendamustine (Treanda)
Bendamustine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is also being studied in the treatment of other types of cancers, including multiple myeloma.
BL-8040
BL-8040 is a novel CXC4 antagonist that blocks chemicals in the cancer cell responsible for growth and division and blood vessel development.
Bortezomib (Velcade)
Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. It is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bortezomib is given as an injection under the skin (subcutaneously) or injected into a vein through an IV.
Carfilzomib (Kyprolis)
Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy.
Daratumumab (Darzalex)
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
Dendritic Cell Fusion Vaccine
Dendritic Cell Fusion Vaccines are a type of immunotherapy where our own cells, in this case, dendritic cells, are loaded with tumor antigens to help the immune system recognize and mount a response to those cancer cells present in the body.
Denosumab (Xgeva)
Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.
Elotuzumab (Empliciti)
Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.
Ixazomib (Ninlaro)
Ixazomib is an oral proteasome inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lenalidomide (Revlimid)
Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.
Natural Killer (NK) Cells
Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
Panobinostat (Farydak)
Panobinostat is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It has been approved to be used in combination with bortezomib and dexamethasone to treat people with multiple myeloma who have received at least two other standard treatments (including bortezomib and an immunomodulating agent).
Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13)
Prevnar 13 is a vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae for the prevention of pneumococcal disease in immunocompromised patients with cancer.
PVX-410
PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.
Selinexor
Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
SurVaxM
SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.
Survivin Vaccine
Survivin Vaccine can work by stimulating the immune system to create T-Cells that recognize and attack Survivin, a tumor antigen.
T Cells
A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.
Trivalent Influenza Vaccine
Trivalent Influenza Vaccine is an annually formulated vaccine that contains the three strains of influenza projected to be prevalent in the coming season.